Announced Thu, 4 Jun, 2026 · 16:29 IST
Venus Remedies renews in-house R&D recognition from DSIR
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.8%1-day move
₹1555.80
prior close
₹1593.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+1.0+2.5+2.5+5.8+3.5+4.5+10.2+15.7+19.0+24.0+5.2-2.0+6.4
Up moveDown movePending
AI summary
Venus Remedies has renewed its Research and Development recognition from the Government of India's DSIR for its R&D unit VMRC. The recognition supports work in antimicrobial resistance, covering VRP-034, a novel polymyxin B formulation holding USFDA QIDP designation, and the GASAR resistance surveillance study.
Likely market impact
Renewal of government R&D recognition supports ongoing antimicrobial research pipeline, no direct revenue impact.